Tag Archives: Tufts Center for Drug Development

Breaching the Great Wall: Major Pharma Changes Proposed in China

With a revision of China’s basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. Dr. Wang Chenguang, Dean of Tsinghua Law School Behind the vaulting growth statistics that make China the centerfold in Big Pharma’s global playbook is a […]
Posted in compliance, Emerging Markets, Global, IP, R&D, Regulatory | Also tagged , , , , , , , , , | 3 Comments

Tufts R&D Outlook for 2011: Pain Mixed with Promise

The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for […]
Posted in FDA, Gene therapy, R&D, Regulatory | Also tagged , , , , , | 1 Comment
  • Categories

  • Meta